Abstract
As the COVID-19 pandemic continues, researchers seek to identify efficacious treatments. Current approaches to COVID-19 therapeutics focus on antiviral agents, convalescent plasma, monoclonal antibodies, immunomodulators and more traditional therapies such as steroids [1-6]. Reversing disturbances in coagulation has also been identified as a priority area for candidate therapies, such as through the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 adaptive clinical trial (ACTIV-4) which is currently evaluating aspirin, heparins and apixaban [7]. Since there is a clear relationship between mechanisms of coagulation and the immune response, it is possible that reversing disturbances in coagulation may diminish the dysregulated immune response observed in COVID-19. The basis for this hypothesis is described below and is followed by discussion of a proposed candidate therapy – activated protein C. By treating COVID-19 patients using a novel approach, which does not focus on immune-based or antiviral treatments, but instead which addresses both the anti-thrombotic and inflammatory consequences of infection, the hope is that new therapeutic targets can be considered and new candidate therapies, such as activated protein C, may be evaluated.
Keywords: Activated protein C; COVID-19; COVID-19 therapeutics.
【저자키워드】 COVID-19, activated protein C, COVID-19 therapeutics., 【초록키워드】 convalescent plasma, immune response, clinical trial, therapy, adaptive, COVID-19 pandemic, Infection, heparin, monoclonal antibodies, Steroids, COVID-19 therapeutics, immune, Coagulation, immunomodulator, Protein, immunomodulators, Antiviral agents, Aspirin, mechanism, COVID-19 patients, Therapies, Hypothesis, Inflammatory, Hope, therapeutic target, steroid, followed by, protein C, apixaban, heparins, therapeutic interventions, dysregulated immune response, researcher, antiviral treatments, approach, consequence, current, described, identify, evaluated, activated, treating COVID-19 patient, 【제목키워드】 Treatment, Protein, activated,